Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.41 |
| ▸ | METAP2 | P50579 | 4/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23715831 | 0.69 | S1PR3 (0.47) | SLC6A3 | |
| SCHEMBL23716290 | 0.68 | SLC6A4 (0.38) | SLC6A3LMNAMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL23715797 | 0.68 | S1PR3 (0.35) | NPSR1 | |
| SCHEMBL23716419 | 0.68 | SLC6A3 (0.35) | SLC6A3 | |
| SCHEMBL23715786 | 0.63 | ALDH1A1 (0.41) | LMNAHTTSMN1; SMN2 | |
| SCHEMBL23716330 | 0.62 | MDM2 (0.38) | LMNAMEN1HTTKMT2A | |
| SCHEMBL7809289 | 0.61 | SLC6A3 (0.41) | SLC6A3LMNA | |
| SCHEMBL19134192 | 0.60 | KMT2A (0.68) | LMNAMEN1MAPTHTTKMT2A | |
| SCHEMBL17975810 | 0.58 | HPGD (0.57) | SLC6A3MEN1MAPTHTTKMT2A | |
| SCHEMBL9152734 | 0.58 | ALDH1A1 (0.46) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3209732-B1 | SPHINGOSINE-1-PHOSPATE RECEPTOR MODULATORS FOR TREATMENT OF CARDIOPULMONARY DISORDERS | SCRIPPS RESEARCH INST (US) | 2021-08-04 | — | — | EP | disclosed |